OptiBiotix Health PLC – OPTI – Final Results
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its audited results for the period ended 31 December 2020.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its audited results for the period ended 31 December 2020.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its audited results for the period ended 31 December 2019. During the period, the Company has met a significant number of important objectives that continue to build value for shareholders.
OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, provides the following unaudited preliminary revenue figures and a trading, commercial, and strategic update ahead of the Group’s final results for the year ended 30 November 2019.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces the departure of Christina Wood as Executive Sales & Marketing Director by mutual agreement.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces its results for the six months ended 31 May 2019.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a non-exclusive license agreement with Tenshindo, Co. Ltd. for the use of Lactobacillus plantarum LPLDL® (“LPLDL®”) in cardiovascular food supplements in Japan.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Kappa Bioscience AS for the use of Lactobacillus plantarum LPLDL® in a new application area within cardiovascular health.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, highcholesterol, diabetes and skin care, announces it has entered into a manufacturing, supply and distribution agreement with Agropur MSI, LLC.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Stephen Prescott as Chief Executive Officer (CEO) of its wholly-owned subsidiary, ProBiotix Health Ltd.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it has appointed Extensor as its exclusive distributor of OptiBiotix’s own label GoFigure® consumer weight management products in Poland.